EA202192903A1 - Кристаллическая форма ингибитора plk4 - Google Patents
Кристаллическая форма ингибитора plk4Info
- Publication number
- EA202192903A1 EA202192903A1 EA202192903A EA202192903A EA202192903A1 EA 202192903 A1 EA202192903 A1 EA 202192903A1 EA 202192903 A EA202192903 A EA 202192903A EA 202192903 A EA202192903 A EA 202192903A EA 202192903 A1 EA202192903 A1 EA 202192903A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystalline form
- plk4 inhibitor
- compound
- plk4
- inhibitor
- Prior art date
Links
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 title 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837858P | 2019-04-24 | 2019-04-24 | |
| PCT/CA2020/050535 WO2020215155A1 (en) | 2019-04-24 | 2020-04-23 | Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192903A1 true EA202192903A1 (ru) | 2022-02-09 |
Family
ID=72940551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192903A EA202192903A1 (ru) | 2019-04-24 | 2020-04-23 | Кристаллическая форма ингибитора plk4 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12325700B2 (enExample) |
| EP (1) | EP3959209A4 (enExample) |
| JP (1) | JP7705351B2 (enExample) |
| KR (1) | KR20220004102A (enExample) |
| CN (1) | CN113966330B (enExample) |
| BR (1) | BR112021021106A2 (enExample) |
| CA (1) | CA3137191A1 (enExample) |
| EA (1) | EA202192903A1 (enExample) |
| IL (1) | IL287394A (enExample) |
| MA (1) | MA55767A (enExample) |
| MX (1) | MX2021012993A (enExample) |
| SA (1) | SA521430647B1 (enExample) |
| SG (1) | SG11202111003UA (enExample) |
| TW (1) | TWI862582B (enExample) |
| WO (1) | WO2020215155A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013225A (es) | 2021-05-11 | 2024-01-15 | Oric Pharmaceuticals Inc | Inhibidores de la cinasa 4 similar a polo. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| US20110201818A1 (en) | 2007-09-25 | 2011-08-18 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| JP2011506494A (ja) | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| ES2660146T3 (es) | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| PT2556071T (pt) | 2010-04-06 | 2016-11-22 | Univ Health Network | Inibidores de quinase e seus usos no tratamento de cancro |
| WO2012000103A1 (en) | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| KR20130105675A (ko) | 2010-11-25 | 2013-09-25 | 라티오팜 게엠베하 | 아파티닙의 신규 염 및 다형 |
| US9580390B2 (en) | 2011-10-12 | 2017-02-28 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| ES2908200T3 (es) | 2013-10-18 | 2022-04-28 | Univ Health Network | Tratamiento para el cáncer de páncreas |
| HRP20190564T1 (hr) | 2013-10-18 | 2019-05-17 | University Health Network | Sol i kristalni oblici inhibitora plk-4 |
-
2020
- 2020-04-23 EP EP20795605.3A patent/EP3959209A4/en active Pending
- 2020-04-23 JP JP2021562948A patent/JP7705351B2/ja active Active
- 2020-04-23 CN CN202080030678.8A patent/CN113966330B/zh active Active
- 2020-04-23 MA MA055767A patent/MA55767A/fr unknown
- 2020-04-23 MX MX2021012993A patent/MX2021012993A/es unknown
- 2020-04-23 BR BR112021021106A patent/BR112021021106A2/pt unknown
- 2020-04-23 TW TW109113591A patent/TWI862582B/zh active
- 2020-04-23 US US17/605,108 patent/US12325700B2/en active Active
- 2020-04-23 EA EA202192903A patent/EA202192903A1/ru unknown
- 2020-04-23 KR KR1020217037777A patent/KR20220004102A/ko not_active Ceased
- 2020-04-23 SG SG11202111003UA patent/SG11202111003UA/en unknown
- 2020-04-23 CA CA3137191A patent/CA3137191A1/en active Pending
- 2020-04-23 WO PCT/CA2020/050535 patent/WO2020215155A1/en not_active Ceased
-
2021
- 2021-10-19 IL IL287394A patent/IL287394A/en unknown
- 2021-10-20 SA SA521430647A patent/SA521430647B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004102A (ko) | 2022-01-11 |
| TWI862582B (zh) | 2024-11-21 |
| JP2022530028A (ja) | 2022-06-27 |
| BR112021021106A2 (pt) | 2021-12-14 |
| MA55767A (fr) | 2022-03-02 |
| MX2021012993A (es) | 2021-12-10 |
| JP7705351B2 (ja) | 2025-07-09 |
| CN113966330B (zh) | 2024-09-13 |
| WO2020215155A8 (en) | 2020-11-26 |
| CN113966330A (zh) | 2022-01-21 |
| US20220204494A1 (en) | 2022-06-30 |
| US12325700B2 (en) | 2025-06-10 |
| CA3137191A1 (en) | 2020-10-29 |
| WO2020215155A1 (en) | 2020-10-29 |
| IL287394A (en) | 2021-12-01 |
| SA521430647B1 (ar) | 2024-01-27 |
| EP3959209A4 (en) | 2022-12-28 |
| EP3959209A1 (en) | 2022-03-02 |
| TW202104216A (zh) | 2021-02-01 |
| SG11202111003UA (en) | 2021-11-29 |
| AU2020264143A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550045A1 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| MX2023009037A (es) | Compuesto de pirimidopirano. | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| UA83720C2 (ru) | Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| EA200300107A1 (ru) | Кристаллические формы трет-бутиламиновой соли периндоприла | |
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| MX2021003427A (es) | Nuevos oxadiazoles. | |
| GEAP202415849A (en) | Crystalline salt forms of kinase inhibitor | |
| JOP20210072A1 (ar) | ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه | |
| EA202190880A1 (ru) | Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение | |
| EA202092393A1 (ru) | Кристаллическое соединение оксазола | |
| MX2021004386A (es) | Compuestos novedosos. | |
| WO2018125983A8 (en) | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| CR20240173A (es) | Compuestos de cd73 | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors | |
| WO2020003272A8 (en) | An improved process for the preparation of venetoclax | |
| MX2025009371A (es) | Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello | |
| MY209356A (en) | A xinafoate salt of a jak inhibiting compound | |
| MY202100A (en) | Crystal | |
| MX2022005201A (es) | Formulaciones de naftalimida dimerica. | |
| WO2020251871A3 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |